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Introduction: The occurrence of clear cell tumors in the bladder is not uncommon. Clear cell dysplasia is
well-described and characterized by focal replacement of transitional mucosa by cells with abundant clear
cytoplasm, nuclear enlargement, and a granular chromatin pattern. Clear cells can also be seen in clear cell
adenocarcinoma, which is rare, comprising 0.5% to 2.0% of the reported bladder carcinomas. Other clear cell tumors
found in the bladder to be considered in the differential diagnosis are tumors of Müllerian origin and metastatic
lesions, such as renal cell carcinoma, clear cell sarcoma, and malignant melanoma. Clear cell urothelial carcinoma is
exceedingly rare, with only nine clinical cases described in the literature.
Case presentation: We report the case of a 75-year-old Caucasian man who presented with intermittent
hematuria, in whom a bladder tumor was identified. A final histopathology examination of a cystoprostatectomy
specimen revealed a pT3b, G3 urothelial carcinoma of clear cell type (>90% clear cells) and a prostatic adenocarcinoma
of Gleason grade 3+3 (score=6). The bladder tumor consisted of sheets of malignant cells with severe nuclear
atypia and abundant clear cytoplasm; no glandular or tubular structures were identified. Tumor cells were periodic
acid-Schiff positive and negative after diastase treatment; additional mucicarmine and oil red O stains were negative.
Immunohistochemical stains showed the tumor cells positive for cytokeratin 7 (CK7), p63 (>80% nuclei), p53 (about
30% nuclei), vimentin, E-cadherin, cluster of differentiation (CD10), and Ki-67 (>70% nuclei). Stains for cell adhesion
molecule 5.2 (CAM 5.2), CD117, cytokeratin 20 (CK20), human melanoma black 45 (HMB-45), paired box protein (PAX 8),
placental alkaline phosphatase (PLAP), prostate specific antigen (PSA), renal cell carcinoma (RCC), cancer antigen 25 (CA25),
leukocyte common antigen (LC), S-100 protein, and uroplakin III were all negative.
Conclusions: The tumor marker profile was consistent with clear cell type carcinoma of urothelial origin.
Within the differential diagnoses, we ruled out other possible tumor types such as urothelial carcinoma with
focal clear cell differentiation, clear cell adenocarcinoma, Müllerian tumors, and metastatic disease.
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Urinary bladder carcinomas that differ on histology from
typical urothelial carcinomas were reviewed by Young and
Eble [1]. These tumors account for approximately 15% of
all bladder carcinomas and fall into four major categories:
variant forms of urothelial carcinoma, squamous cell car-
cinoma, adenocarcinoma, and undifferentiated carcinoma
[1]. Variant forms of urothelial carcinoma include squa-
mous and glandular differentiation, but these are only* Correspondence: Francisco.LaRosa@ucdenver.edu
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elsewhere in the tumor [1].
The identification of clear cell tumors in the bladder is
not uncommon [2]. Clear cell dysplasia is well-described
and characterized by focal replacement of transitional
mucosa by cells with abundant clear cytoplasm, nuclear
enlargement, and a granular chromatin pattern [3]. Clear
cells can also be seen in clear cell adenocarcinoma,
which is rare, comprising 0.5% to 2.0% of the reported
bladder carcinomas [1]. The name clear cell adenocar-
cinoma is used because of the histologic similarity to
clear cell adenocarcinomas of the female genital tract
[1]. Clear cell urothelial carcinoma is exceedingly rare,
with only nine clinical cases described in the literatured. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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be considered in the differential diagnosis are metastatic
lesions, such as renal cell carcinoma or melanoma.
We report the case of a male patient who underwent
radical cystoprostatectomy for a urinary bladder tumor
featuring rounded to polygonal cells with abundant clear
cytoplasm, which deeply infiltrated the vesical wall. We
discuss the morphologic features, immunohistochemical,
and special staining pattern, and review the literature on
clear cell urothelial carcinoma.
Case presentation
Our patient was a 75-year-old Caucasian man with a his-
tory of intermittent hematuria for a few days the month
preceding a cystoscopy. He was otherwise asymptomatic
and denied bone pain, jaundice, hemoptysis, or weight
loss. Of clinical relevance, he was a former smoker who
quit 21 years ago and had been using smokeless tobacco
for the last 16 years. His referring institution performed
a cystoscopy revealing a bladder tumor and a biopsy that
showed a high-grade urothelial carcinoma with widespread
clear cell differentiation (>80%), with severe necrosis, and
extensive invasion into the muscularis propria. An ultra-
sound at the time showed a large urinary bladder mass
with no evidence of extravesical disease, and mild right-
sided hydronephrosis suggestive of obstruction of his distal
right ureter. Because of an elevated serum creatinine of
1.6mg/dL, neoadjuvant chemotherapy was not attempted.
A radical cystoprostatectomy was soon performed at our
institution. On follow-up, his creatinine levels continued to
be elevated and cisplatinum-based chemotherapy was fur-
ther deferred. After one year of follow-up, our patient had
no evidence of disease recurrence.
The cystoprostatectomy specimen was fixed in 10% buf-
fered formalin, and the prostate was dissected out for inde-
pendent processing. Macroscopic examination showed a
fungated and hemorrhagic urinary bladder mass arising
from the mucosal surface, measuring 5.5×5.0×2.3cm,Figure 1 Macroscopic examination of the cystectomy specimen. Gross
5.5×5.0×2.3cm, involving the inferior right lateral wall, and with near oblite
full thickness invasion through the detrusor muscle and into the perivesicainvolving the inferior right lateral wall, and with near
obliteration of the right ureteral orifice (Figure 1). Rep-
resentative sections of the bladder tumor were embed-
ded in paraffin, sectioned at 5μm, and stained with
hematoxylin-eosin. Microscopic examination revealed a
tumor consisting of sheets and nodules of rounded to
polygonal malignant cells with enlarged nuclei, promin-
ent nucleoli, and abundant clear cytoplasm (>90% clear
cell differentiation) (Figure 2A,B). No glandular differ-
entiation or hobnail cells were observed. The tumor in-
vaded through the full thickness of the muscularis
propria (detrusor muscle) into the perivesical adipose
tissue, approaching within 0.5mm of the perivesical se-
rosal surface (pathology stage pT3b). Extensive necrosis
accompanied by prominent acute inflammation was
present. Lymphovascular invasion was identified. Focal
carcinoma in situ was present in the adjacent surface
urothelium. This tumor showed very similar histopath-
ology to the prior bladder biopsy from the referring
institution.
The prostate gland revealed multifocal and bilateral
prostatic adenocarcinoma, Gleason grade 3+3 (score=6),
measuring 6mm in greatest dimension and involving <5%
of the prostate. There was focal extension of prostatic
adenocarcinoma into the left posterior surgical margin
(2mm in length).
To characterize the content of the clear, vacuolated
cytoplasm of the malignant cells in the bladder tumor,
special histochemical stains were performed. The tumor
cells were positive for periodic acid-Schiff (PAS) staining,
which disappeared with diastase (PAS-D) treatment
(Figure 2C,D). The cells were negative for mucicarmine
staining and for oil red O on frozen sections of the
formalin-fixed tissue. This staining pattern confirmed
the cells contained polysaccharides such as glycogen, as
opposed to mucin or fat.
Immunohistochemical stains were done with the following
markers: Cytokeratin (CK) 7, CK20, Cell adhesion moleculeexamination showing a fungated hemorrhagic mass measuring
ration of the right ureteral orifice (left). Cut section of the tumor shows
l adipose tissue (right).
Figure 2 Hematoxylin and eosin staining of the cystectomy specimen. (A) Sheets of clear cells can be seen invading through the muscularis
propria into the perivesical adipose tissue (10× objective). (B) Rounded to polygonal malignant cells with severe nuclear atypia, prominent
nucleoli, and abundant, clear cytoplasm seen under a 40× objective. (C) These cells were positive for periodic acid-Schiff, which (D) disappeared
with diastase treatment. (E-H) Immunoperoxidase stains show tumor cells with strong positive membrane staining for CK7 (E), approximately
30% nuclear staining for p53 antigen (F), >80% nuclear staining for p63 antigen (G), and >70% nuclear staining for Ki-67 (MIB-1) antigen
(H). Figures B through H at 40× objective.
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Cluster of differentiation (CD) 10, Paired box protein (PAX)
8, Renal cell carcinoma (RCC), CD117, Placental alkaline
phosphatase (PLAP), S-100 protein, Human melanoma black
(HMB) 45, Prostate Specific Antigen (PSA), Cancer Antigen
125 (CA-125), and Ki-67. Appropriate positive and negative
controls were used. The tumor cells were positive for CK7
(Figure 2E), p53 (approximately 30% nuclear, Figure 2F), p63
(>80% nuclear, Figure 2G), Vimentin, E-cadherin (focal),
CD10 (patchy), and Ki-67 (>70% nuclear, Figure 2H). The
tumor cells were negative for Cancer antigen 125, CAM
5.2, CD117, CK20, HMB-45, PAX 8, PLAP, Prostate
specific antigen, S-100 protein, Uroplakin III, and RCC.
Additionally, the cells were negative for Leukocyte com-
mon antigen, a test previously performed and reported by
the referring institution. This tumor marker profile ruled
out clear cell carcinoma of Müllerian origin and other
tissue origins and was most diagnostic of a primary
urothelial origin. The immunostain and histochemical
stain results are detailed in Table 1.
Discussion
Urothelial carcinoma is the most common tumor arising in
the urinary tract [4], and the most common variants have
glandular or squamous differentiation [1]. Little is known,
however, about urothelial carcinoma with predominantly
clear cells, other than the few clinical cases reported previ-
ously, as listed in Table 2 [5].Although the presence of clear cells in otherwise typical
urothelial carcinoma is not uncommon [3,4], the tumor in
this case had clear cells far in excess of what is normally seen
in urothelial carcinoma. To the best of our knowledge, no
study to date has shown that clear cell dysplasia progresses
to clear cell urothelial carcinoma [3,4]. “In fact, the infre-
quent reporting of clear-cell transitional cell carcinoma,
when compared with the relatively common observation of
clear-cell dysplasia, makes this unlikely,” per Braslis et al. [4].
Regarding PAS staining, Braslis and colleagues similarly re-
ported dense and spotty positivity for cytoplasmic glycogen in
one of their cases of clear cell urothelial carcinoma (Table 2)
[4]. Normal urothelium contains glycogen, and positive re-
activity of urothelial carcinomas for glycogen was explored by
Kotliar and colleagues [6]. They selected 24 random urothe-
lial carcinomas ranging from low-grade superficial papillary
tumors to high-grade invasive tumors [6]. Approximately two
thirds of tumors, despite their non-clear cytoplasm, showed
varying degrees of PAS positivity that disappeared with
diastase digestion (PAS-D). The overall apparent pattern of
PAS/PAS-D reactivity correlated with tumor grade; in gen-
eral, low-grade superficial urothelial cell carcinomas tended
to have stronger diffuse staining, whereas poorly differenti-
ated tumors tended to have negative or focal positivity [6].
Differential diagnosis
The finding of a clear cell carcinoma in the urinary tract
usually implies the diagnosis of an adenocarcinoma [6].
Table 1 Special immunoperoxidase and histochemical stains
Antibody specificity Tumor cell reactivity Source Clone Positive controls
Cytokeratin 7 Approx. 75%, cell membrane and cytoplasm Dako OV-TL12/30 Breast carcinoma
p53 Approx. 30%, nuclear Dako DO-7 Breast cancer
p63 >80%, nuclear Biocare 4A4 Breast myoepithelial cells
Vimentin Approx. 80%, cell membrane and cytoplasm Ventana 3B4 Salivary gland
Ki-67 >70%, nuclear Ventana 30-9 Tonsil
CD10 Approx. 15%, cell membrane Cell Marque 56C6 Tonsil
E-cadherin Approx. 10%, cell membrane Cell Marque ECH-6 Breast ductal carcinoma
CA125 Negative Cell Marque OC1-25 Ovarian carcinoma
CAM 5.2 Negative Becton Dickinson CAM 5.2 Cholangiocarcinoma
CD117 Negative Dako c-kit Gastrointestinal stromal
Cytokeratin 20 Negative Biocare Ks 20.8 Large intestinal epithelium
MAA Negative Ventana HMB-45 Melanoma
PAX 8 Negative Cell Marque MRQ-50 Nonmucinous ovarian
PLAP Negative Ventana NB10 Placenta
PSA Negative Ventana Rabbit polyc. Prostate
RCC Negative Cell Marque PN-15 Renal cell tubular epithelium
S-100 protein Negative Ventana 4C4.9 Melanoma
Uroplakin III Negative Cell Marque SP73 Urothelial carcinoma
Special histochemical stain Reactivity
PAS Positive cytoplasm Ventana Cirrhotic liver
PAS-diastase Negative Ventana Cirrhotic liver
Mucicarmine Negative Manual Small intestinal epithelium
Oil red O (frozen section) Negative Manual Perivesical adipose tissue
CA, Cancer antigen; CAM, Cell adhesion molecule; CD, Cluster of differentiation; MAA, melanoma-associated antigen; PAS, periodic acid-Schiff; PAX, Paired box
protein; PLAP, Placental alkaline phosphatase; PSA, Prostate-specific antigen; RCC, Renal cell carcinoma.
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affecting the female urethra, although it may occur in men
and in the urinary bladder [6]. These adenocarcinomas are
characterized by tubules, cysts, papillae, or diffuse sheets of
clear cells containing abundant, clear glycogen-rich cyto-
plasm [1]. The tumor cells lining the tubules and cysts
may be cuboidal, hobnail, or flattened and usually show
strong immunostaining for PAX 8 [1,8]. A signet-ring cell
type is observed in some cases and is distinguished by
abundant intracytoplasmic mucin globules of varying size
displacing the nucleus to the cell periphery [4]. By con-
trast, clear cell urothelial carcinomas, as observed in our
case, do not show luminal formation or hobnail cells, and
are mucin and PAX8 negative.
The lipoid-cell variant of urothelial carcinoma could also
be considered in the differential diagnosis. De Giorgi and
colleagues described a bladder tumor featuring poorly dif-
ferentiated, pleomorphic cells with nuclear pleomorphism
and large, optically clear intracytoplasmic vacuoles impart-
ing an adipocytic appearance [9]. Leroy and colleagues did
stains on such tumors and found that mucin stain, alcian
blue and PAS stains were negative, implying lipid content[10]. By contrast, clear cell urothelial carcinomas, as ob-
served in our case (oil red O negative), show no lipid cyto-
plasmic content.
Though less likely in the differential diagnoses, we could
still consider a nephrogenic adenoma, especially the variant
of a nephrogenic adenoma-like clear cell carcinoma. Herawi
and colleagues did a study comparing clear cell adenocarcin-
oma, nephrogenic adenoma-like clear cell adenocarcinoma,
and nephrogenic adenoma [11]. Features discriminating
nephrogenic adenoma-like clear cell adenocarcinoma from
nephrogenic adenoma included occasional clear cells, a
prominent pleomorphism, and extensive muscular invasion
[11]. The cytologic atypia of nephrogenic adenoma falls
short of that seen in our case of clear cell urothelial carcin-
oma. In addition, nephrogenic adenoma has a low Ki-67 rate
(0% to 5%) and is negative for p53, whereas in our case the
Ki-67 and p53 nuclear expressions were very high (>70%
and approximately 30%, respectively) [11].
The most likely clear cell metastatic disease to consider
would be renal cell carcinoma. However, renal cell carcin-
oma metastasis to the bladder is very rare, with only
approximately 30 cases reported in the literature [7]. On
Table 2 Bibliographic references of case reports of clear cell urothelial carcinoma
Patient Clinical presentation Pathology findings Selected testing results Additional history Follow-up Report
71 M Painless hematuria Left wall involvement into perivesical fat Glycogen positive Prostatic adenocarcinoma Death after 20 months Kotliar et al. [6]
Mucin negative Gleason grade 2+3 (>25%) 1995
PSA negative
PSAP negative
EM: no gland formation
58 F Dysuria and infected
urethral cyst with pyuria
Urethral involvement with invasion Glycogen positive Data not available Kotliar et al. [6]
1995Mucin negative
70 F Intermittent, gross hematuria Right upper ureter stenosing lesion Glycogen positive Alive at six months Braslis et al. [4]
Mucin negative 1997
70 M Frequency, urgency, anuria Red, irregular mucosa Invasion
within 0.5mm of detrusor muscle.
Data not available Braslis et al. [4]
1997
70 M Asymptomatic hematuria Left wall tumor, muscle invasive,
treated with TURBt
History of clear cell renal cell
carcinoma, pulmonary metastasis
No recurrence after Yamashita et al. [7]
2006seven months
69 F Gross hematuria Right wall tumor, treated with TURBt Chronic renal failure, hemodialysis
treatment
No recurrence after Isono et al. [13]
201020 months
82 M Asymptomatic Deep infiltration of muscularis propria GATA3+ History of clear cell renal cell
carcinoma,
Alive at 12 months Rotellini et al. [2]
UroVysion fluorescence
in situ hybridization Furhman grade 2 2010
67 M Progressive lower urinary
tract symptoms
Bilateral ureteral stenosis due to muscle
invasive mass in trigone, treated with TURBt
Death at 14 weeks Kramer et al. [5]
2012
75 M Intermittent hematuria Right wall with near obliteration of ureter
and invasion into fat
Glycogen positive Prostatic adenocarcinoma Alive at ten months Present case
Mucin negative Gleason grade 3+3 (<5%) 2013
Lipid negative
PSA negative
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by compact nests of cells with clear, abundant cytoplasm
and delicate blood vessels [12]. This vascular network was
not present in our case. In difficult cases, immunohisto-
chemistry may be helpful. Renal cell carcinoma is typically
negative for CK7 and CK20, but positive for RCC antigen,
CAM 5.2, Vimentin, and PAX 8, in contrast to our case
presented here [7].
Clear cell carcinomas can also arise from other organs
including prostate, lung, breast, uterus, ovary, and vagina
[4,5,7]. The latter sites are in females, and thus not applic-
able to this case. Prostatic origin however, is a consideration
because our patient was discovered to have prostatic adeno-
carcinoma. Nevertheless, the prostate cancer observed in
this case was low grade and focal (<5% of the gland was
involved). As described previously, no glandular formation
was seen in the bladder tumor, the clear cell vacuoles were
negative for lipid content (lipid material has been reported
in prostatic adenocarcinoma [4]), and the tumor was p63
positive and PSA negative.
Before identifying the tumor as a carcinoma, we also con-
sidered metastatic melanoma, clear cell sarcoma, and semi-
noma. These other possibilities were excluded by negative
staining for S-100 protein, HMB-45, CD117, and PLAP,
whereas positive staining for CK7 supported the diagnosis
of carcinoma.
Prognosis
The clinical course of clear cell variant urothelial carcinoma
of the bladder is currently not known due to the lack of a
larger number of cases (Table 2) [5]. Our patient in this
case was alive ten months after initial presentation. In one
of the cases reported by Braslis and colleagues, the longest
patient survival was reported as at a six-month follow-up
[4]. A less aggressive course was also reported in two
patients who were treated with transurethral resection of
the bladder tumor; even though one had detrusor muscle
invasion, both were free from recurrence after seven and 20
months [5,7,13].
In a case report by Kramer and colleagues, the urothelial
clear cell carcinoma showed a very aggressive behavior with
rapid local recurrence and development of peritoneal
carcinomatosis from which the patient survived only 14
weeks after diagnosis [5]. A similar aggressive course was
described by Kotliar and colleagues, in which a 71-year-old
man underwent a radical cystoprostatectomy and two
pelvic lymph nodes were found to be positive for metastatic
disease; despite adjuvant chemotherapy, their patient died
after 20 months [5,6].
Future directions
Hepatocyte nuclear factor-1β was tested in clear cell adeno-
carcinomas of the bladder and urethra by Brimo and
colleagues in 18 cases and was found to be a useful markerin differentiating clear cell adenocarcinomas from invasive
high-grade urothelial carcinoma and other types of bladder
adenocarcinomas [14]. It would be interesting to apply the
marker to clear cell urothelial carcinoma to learn about the
staining pattern of the tumor and, possibly, for diagnostic
utility.
Conclusion
The glycogen-rich, clear cell variant of urothelial carcin-
oma is an exceedingly rare tumor which we report in a
case where malignant clear cells were far in excess of that
seen in usual urothelial carcinomas. Immunohistochemi-
cal and histochemical stains helped exclude more com-
mon malignant tumors primary to the bladder, as well as
metastatic lesions. Given the small number of reported
cases, prognosis is not known; the continued report of
these cases may eventually shed light on the biology and
prognosis of these very rare tumors. Our patient is alive at
the time of writing and constantly followed in our hospital
system.
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